Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease

Biotechnology

Enterin

Enterin's headquarters in Philadelphia, PA, United States

Christina Gallagher

Michael Zasloff

Richard S. Larson

William Kinney

Hilde Williams

D. Phillip Cox

Lisa Bruno

Joseph Costa

Chris Dobson

Michael Camilleri

Linda Greensmith

Wolfgang Kunze

Richard D. Propper

Mark Finn

Barry Miller

Jay Brammer

Alexander Fleming

Roger Mills

Don Munoz

Patrik Brundin

Robert A. Hauser

Rajeev Kumar

K Ray Chaudhuri

Alan Moses

Michael Zemel

Thyagarajan Subramanian

Anthony Schapira

Elizabeth Cho-Fertikh

Tom Laughren

The Advisory Team at Enterin leverages its extensive scientific and regulatory expertise to guide the development and implementation of novel drug therapies that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. With a diverse group of scientific advisors, board members, and regulatory strategists, the team ensures that Enterin's groundbreaking treatments meet rigorous scientific and regulatory standards while advancing innovative research and clinical strategies.

Advisory Team

The Board Members and Executives at Enterin are responsible for overseeing the strategic direction, financial health, and operational efficiency of the company. They guide the development and commercialization of novel drugs targeting the gut-brain axis in neurodegenerative diseases, ensuring regulatory compliance and fostering investor relations to support long-term growth.

Board Members and Executives

The Leadership Team at Enterin is responsible for guiding the company’s strategic vision and ensuring the successful development and commercialization of its groundbreaking drug aimed at repairing the gut-brain axis in neurodegenerative disease patients. This team comprises key executives who oversee research and development, clinical trials, manufacturing, and overall operations, driving innovation while ensuring regulatory compliance and effective market strategies. Their collective expertise positions Enterin at the forefront of therapeutic advancements in neurodegenerative health.

Leadership Team

The Clinical Operations Team at Enterin is responsible for overseeing the planning, coordination, and execution of clinical trials. This includes designing study protocols, managing logistics, ensuring regulatory compliance, and supervising the supply chain for trial materials to support the development of Enterin's novel drug targeting the gut-brain axis in neurodegenerative diseases.

Clinical Operations Team

The Medical and Scientific Team at Enterin is responsible for leading research and development efforts to innovate and optimize treatments that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. This team combines medical expertise and scientific research to ensure the efficacy and safety of the novel drug, oversee clinical trials, and collaborate with regulatory bodies for approvals.

Medical and Scientific Team

Enterin

Org chart

Board & advisors

Teams

Advisory Team

Board Members and Executives

Leadership Team

Clinical Operations Team

Medical and Scientific Team

Offices

Enterin

Org chart

Board & advisors

Teams

Advisory Team

Board Members and Executives

Leadership Team

Clinical Operations Team

Medical and Scientific Team

Offices

Related companies